Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.45 |
| ▸ | PPARG | P37231 | 7/20 | 0.45 |
| ▸ | PPARD | Q03181 | 7/20 | 0.45 |
| ▸ | PPARA | Q07869 | 7/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.45 |
| ▸ | TSHR | P16473 | 4/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TLR2 | O60603 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | FABP4 | P15090 | 2/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.45 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.45 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6830568 | 0.94 | FFAR4 (0.52) | AKR1B1GPR84PPARGPPARDPPARA | |
| SCHEMBL8984375 | 0.92 | FFAR4 (0.50) | CA2GPR84PPARGPPARDPPARA | |
| SCHEMBL3930979 | 0.92 | CAMK2A (0.44) | CA2AKR1B1GPR84PPARGPPARD | |
| SCHEMBL4875928 | 0.92 | CA2 (0.55) | CA2AKR1B1GPR84PPARGPPARD | |
| SCHEMBL5077959 | 0.91 | FFAR4 (0.53) | AKR1B1GPR84PPARGPPARDPPARA | |
| Trifluoroacetic Acid SCHEMBL3342695 | 0.90 | CA2 (0.41) | CA2AKR1B1GPR84PPARGPPARD | |
| SCHEMBL5082422 | 0.89 | FFAR4 (0.55) | AKR1B1GPR84PPARGPPARDPPARA | |
| SCHEMBL6720816 | 0.88 | CA2 (0.52) | CA2AKR1B1GPR84PPARGPPARD | |
| SCHEMBL28184368 | 0.88 | FFAR4 (0.57) | CA2AKR1B1GPR84PPARGPPARD | |
| SCHEMBL10960622 | 0.86 | FFAR4 (0.60) | AKR1B1GPR84PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008056291-A2 | METHOD OF PRODUCING FATTY ACID HYDROPEROXIDES | FIRMENICH SA (CH) | 2008-05-15 | — | — | WO | disclosed |
| EP-1921134-A1 | Method of producing fatty acid hydroperoxides | Georg-August-Universität Göttingen (DE) | 2008-05-14 | — | — | EP | disclosed |
| US-7179626-B1 | 11-Arachidonate-lipoxygenase mutants | INSTITUT FUR PFLANZENBIOCHEMIE-IPB (DE) | 2007-02-20 | — | — | US | disclosed |
| US-7176204-B2 | Substituted carboxylic acid derivatives | KYORIN PAHRMACEUTICAL CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-7018537-B2 | Chiral stationary phases based on derivatives of 4-amino-3,5-dinitrobenzoic acid | CHIRALLICA D.O.O. (HR) | 2006-03-28 | — | — | US | disclosed |
| US-20050101521-A1 | Substituted carboxylic acid derivatives | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| US-20040144708-A1 | Chiral stationary phases based on derivatives of 4-amino-3,5-dinitrobenzoic acid | EURAND PHARMACEUTICALS LTD. (IE) | 2004-07-29 | — | — | US | disclosed |
| EP-1370356-A1 | CHIRAL STATIONARY PHASES BASED ON DERIVATIVES OF 4-AMINO-3,5-DINITROBENZOIC ACID | EURAND PHARMACEUTICALS LTD. (IE) | 2003-12-17 | — | — | EP | disclosed |
| EP-1348698-A1 | SUBSTITUTED CARBOXYLIC ACID DERIVATIVES | Kyorin Pharmaceutical Co., Ltd. (JP) | 2003-10-01 | — | — | EP | disclosed |
| WO-2002070124-A1 | CHIRAL STATIONARY PHASES BASED ON DERIVATIVES OF 4-AMINO-3,5-DINITROBENZOIC ACID | EURAND PHARMACEUTICALS LTD (IE) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101521-A1 | Substituted carboxylic acid derivatives | PPARG, PPARA, PPARD | CA2 1269/4885AKR1B1 290/4885GPR84 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.